Regarding the clinical outcome, 8/9 patients with MDS/AML died (no outcome data was reported in one patient with MDS), suggesting a dismal prognosis of MDS/AML harboring ERCC6L2 mutations. Here, ERCC6L2 is linked to myelodysplastic syndrome.